Subscribe
shutterstock_281684060_mark_van_scyoc
Mark Van Scyoc / Shutterstock.com
30 July 2020AmericasRory O'Neill

Shkreli says he isn’t responsible for Daraprim ‘monopoly’

Jailed ‘pharma bro’ Martin Shkreli has told a US federal court he is not responsible for  antitrust violations alleged by the  US Federal Trade Commission (FTC).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
States join antitrust suit against ‘pharma bro’ Shkreli
16 April 2020   Six state attorneys have joined a suit filed against incarcerated ‘pharma bro’ Martin Shkreli and his company Vyera Pharmaceuticals for allegedly monopolising the market for a life-saving drug.
Big Pharma
Shkreli inflated price of life-saving drug from federal prison, FTC says
14 August 2020   Martin Shkreli conspired to illegally increase the price of a life-saving drug during phone calls he made from prison, according to the US Federal Trade Commission.
Big Pharma
Judge issues mixed ruling on Shkreli attorney communications
21 August 2020   The FTC should avoid reviewing communications between Martin Shkreli and his attorneys, but these are not protected under the Privacy Act, a New York federal judge has ruled.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
States join antitrust suit against ‘pharma bro’ Shkreli
16 April 2020   Six state attorneys have joined a suit filed against incarcerated ‘pharma bro’ Martin Shkreli and his company Vyera Pharmaceuticals for allegedly monopolising the market for a life-saving drug.
Big Pharma
Shkreli inflated price of life-saving drug from federal prison, FTC says
14 August 2020   Martin Shkreli conspired to illegally increase the price of a life-saving drug during phone calls he made from prison, according to the US Federal Trade Commission.
Big Pharma
Judge issues mixed ruling on Shkreli attorney communications
21 August 2020   The FTC should avoid reviewing communications between Martin Shkreli and his attorneys, but these are not protected under the Privacy Act, a New York federal judge has ruled.

More on this story

Americas
States join antitrust suit against ‘pharma bro’ Shkreli
16 April 2020   Six state attorneys have joined a suit filed against incarcerated ‘pharma bro’ Martin Shkreli and his company Vyera Pharmaceuticals for allegedly monopolising the market for a life-saving drug.
Big Pharma
Shkreli inflated price of life-saving drug from federal prison, FTC says
14 August 2020   Martin Shkreli conspired to illegally increase the price of a life-saving drug during phone calls he made from prison, according to the US Federal Trade Commission.
Big Pharma
Judge issues mixed ruling on Shkreli attorney communications
21 August 2020   The FTC should avoid reviewing communications between Martin Shkreli and his attorneys, but these are not protected under the Privacy Act, a New York federal judge has ruled.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?